Dietmar Berger (Sanofi)
March 2, 2020 02:18 PM ESTUpdated 02:37 PM
R&D

End­ing a gru­el­ing 10-year drought, Sanofi fi­nal­ly wins an OK for an in-house can­cer drug

John Carroll

Editor & Founder

Sanofi has snagged an FDA ap­proval for a top drug in its pipeline, end­ing a 10-year drought of home-grown can­cer drug ap­provals as the new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times